The drug-eluting stent information gap.
Drug-eluting stents are quickly replacing bare-metal stents as the arterial revascularization device of choice. Because nearly all the information we have about patient outcomes with drug-eluting stents is from trials designed for US Food and Drug Administration approval, we are missing some of the information critical to a more comprehensive understanding of how these new devices will perform at the population level.
Yock
Cynthia A
CA
Center for Primary Care and Outcomes Research, Stanford University School of Medicine, 117 Encina Commons, Stanford, CA 94305-6019, USA. yock@healthpolicy.stanford.edu
Yock
Paul G
PG
D020099:Coated Materials, Biocompatible / Q000008:administration & dosage*; D018672:Community Health Planning / Q000592:standards; D015986:Confounding Factors, Epidemiologic; D003327:Coronary Disease / Q000628:therapy; D003625:Data Collection / Q000592:standards; D018795:Device Approval / Q000592:standards; D004346:Drug Information Services / Q000592:standards*; D004358:Drug Therapy / Q000191:economics / Q000295:instrumentation*; D004869:Equipment Safety / Q000592:standards; D006801:Humans; D008422:Materials Testing / Q000592:standards; D009204:Myocardial Revascularization / Q000191:economics / Q000295:instrumentation*; D020380:Needs Assessment / Q000592:standards; D018579:Patient Selection; D012008:Recurrence; D015203:Reproducibility of Results; D012107:Research Design / Q000592:standards; D015607:Stents / Q000191:economics / Q000592:standards*; D013673:Technology Assessment, Biomedical / Q000592:standards; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D020099:Coated Materials, Biocompatible